BaseSpace Sequence Hub Integrations

Amazon Web Services (AWS) is a global leader in cloud computing, providing the broadest and deepest set of cloud capabilities on the market. From compute and storage to advanced analytics, AI, and agentic automation, AWS enables organizations to build, scale, and transform their businesses. Enterprises rely on AWS for secure, compliant infrastructure while startups leverage it to launch quickly and innovate without heavy upfront costs. The platform’s extensive service catalog includes solutions for machine learning (Amazon SageMaker), serverless computing (AWS Lambda), global content delivery (Amazon CloudFront), and managed databases (Amazon DynamoDB). With the launch of Amazon Q Developer and AWS Transform, AWS is also pioneering the next wave of agentic AI and modernization technologies. Its infrastructure spans 120 availability zones in 38 regions, with expansion plans into Saudi Arabia, Chile, and Europe’s Sovereign Cloud, guaranteeing unmatched global reach. Customers benefit from real-time scalability, security trusted by the world’s largest enterprises, and automation that streamlines complex operations. AWS is also home to the largest global partner network, marketplace, and developer community, making adoption easier and more collaborative. Training, certifications, and digital courses further support workforce upskilling in cloud and AI. Backed by years of operational expertise and constant innovation, AWS continues to redefine how the world builds and runs technology in the cloud era.

Pluto was established in 2021 through the efforts of the Wyss Institute at Harvard University. It has built a reputation as a reliable collaborator for numerous life sciences entities nationwide, including both emerging biotech firms and established biopharmaceutical companies. Their innovative cloud-based platform empowers researchers to effectively organize their data, conduct bioinformatics analyses, and generate high-quality interactive visualizations for publication. This versatile platform finds utility in a diverse range of biological applications, such as research in preclinical and translational sciences, advancements in cell and gene therapies, as well as initiatives in drug discovery and development. Scientists across various fields are leveraging Pluto's capabilities to enhance their research outcomes and drive innovation.

Scispot delivers the leading LabOS™ platform for life science organizations, offering a modular suite of ELN, LIMS, SDMS, QMS, and AI tools that adapt to lab needs without coding. Designed for Molecular Diagnostics, Drug Discovery, CROs, and Industrial Biotech, Scispot resolves sample tracking, inventory management, and compliance challenges through one intuitive interface. Seamlessly integrate with 200+ instruments and thousands of applications to eliminate manual data entry while maintaining FDA, GxP, and HIPAA compliance. AI-driven analytics convert lab data into actionable insights that accelerate research outcomes. With rapid implementation, Scispot is trusted by 1000+ lab professionals to streamline operations, reduce administrative burden, and empower teams to focus on breakthrough science. Transform your lab with Scispot's configurable, compliance-ready platform.

The DRAGEN Secondary Analysis system from Illumina provides accurate, comprehensive, and exceptionally efficient processing of next-generation sequencing data. By leveraging a graph reference genome in combination with machine learning methodologies, it achieves outstanding precision. With a highly streamlined workflow, it can fully analyze a 34x whole human genome in roughly 30 minutes when operated on the DRAGEN server v4. Furthermore, it optimizes this process by reducing FASTQ file sizes by as much as five times. This system is proficient in handling diverse types of NGS data, such as whole genomes, exomes, methylomes, and transcriptomes. It has been designed to work seamlessly with the user's chosen platform and can scale to accommodate various needs. DRAGEN analysis is consistently recognized as a frontrunner in accuracy for detecting both germline and somatic variants, supported by its strong performance in industry competitions hosted by precisionFDA. This sophisticated analytical tool enables laboratories of all sizes and specialties to fully leverage their genomic datasets. Additionally, the integration of highly adaptable field-programmable gate array (FPGA) technology allows DRAGEN to implement hardware-accelerated genomic analysis algorithms, significantly improving its efficiency. These advancements firmly establish DRAGEN as an essential asset in the rapidly advancing realm of genomics, enabling researchers to push the boundaries of scientific discovery.